Detalhe da pesquisa
1.
US Food and Drug Administration Analysis of Patient-Reported Diarrhea and Its Impact on Function and Quality of Life in Patients Receiving Treatment for Breast Cancer.
Value Health
; 25(4): 566-570, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35365300
2.
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 22(11): 1573-1581, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656225
3.
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Oncologist
; 26(1): e164-e172, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33017510
4.
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 21(2): 250-260, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31859246
5.
Luminal A Breast Cancer and Molecular Assays: A Review.
Oncologist
; 23(5): 556-565, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29472313
6.
Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy - Authors' reply.
Lancet Oncol
; 21(3): e131, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32135115
7.
FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Clin Cancer Res
; 29(24): 5008-5011, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37594723
8.
U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.
Clin Cancer Res
; 28(6): 1058-1071, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34711631
9.
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.
Clin Cancer Res
; 28(6): 1072-1086, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34711632
10.
U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program.
Clin Cancer Res
; 27(1): 11-14, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32816899
11.
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
JCO Clin Cancer Inform
; 5: 758-767, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34297598
12.
FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs.
Clin Cancer Res
; 27(4): 916-921, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33257426
13.
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer.
Clin Cancer Res
; 27(8): 2126-2129, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33188141
14.
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Clin Cancer Res
; 27(7): 1842-1849, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33168657
15.
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.
Clin Cancer Res
; 26(10): 2284-2289, 2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32001481
16.
Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.
J Clin Oncol
; 37(36): 3475-3483, 2019 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31560580
17.
Advancing Therapies for Asian Americans, Native Hawaiians, and Other Pacific Islanders With Cancer: OCE's Project ASIATICA.
JCO Oncol Pract
; 19(9): 704-705, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37384849
18.
Reexamination of Patient Autonomy and Prior Therapies in Oncology Clinical Trial Eligibility Criteria.
JAMA Oncol
; 8(4): 1-2, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35175315
19.
HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.
Clin Breast Cancer
; 17(1): 76-78, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27692565
20.
Topiramate and metabolic acidosis: an evolving story.
Hosp Pract (1995)
; 45(5): 192-195, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28828886